• Home
  • Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study.

Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study.

Author List
Ahmad Masri, Mandar Aras, Rodney H. Falk, Martha Grogan, Daniel Jacoby, Mathew S. Maurer, Sanjiv J. Shah, Ronald Witteles, Paul W. Wong, Alan X. Ji, Jing Du, Suresh Siddhanti, Uma Sinha, Jonathan C. Fox, Daniel P. Judge
Publication
Journal of cardiac failure
Publication ID (Profile URL)
https://researcherprofiles.org/profile/474657626
Publication Year
2024
Publication Title
Ahmad Masri, Mandar Aras, Rodney H. Falk, Martha Grogan, Daniel Jacoby, Mathew S. Maurer, Sanjiv J. Shah, Ronald Witteles, Paul W. Wong, Alan X. Ji, Jing Du, Suresh Siddhanti, Uma Sinha, Jonathan C. Fox, Daniel P. Judge. Long-term Safety And Tolerability Of Acoramidis (AG10) In Symptomatic Transthyretin Amyloid Cardiomyopathy: 4-year Update From An Ongoing, Phase 2, Open-label Extension Study. Journal of Cardiac Failure. 2024 Jan 1; 30(1):221.